EuroNanoMed

EuroNanoMed
Name	EuroNanoMed
Type	Research funding network
Established	2007
Headquarters	Paris
Region served	European Union
Languages	English, French
Leader title	Coordinating Body
Leader name	European Science Foundation

EuroNanoMed is a European research funding network focused on translational nanomedicine that brought together public institutions, universities, and industry to support collaborative projects in nanoscale diagnostics, therapeutics, and biomaterials. Initiated under regional and transnational research frameworks, it coordinated calls for proposals, peer review, and project monitoring across diverse institutions to accelerate bench-to-bedside innovation. The network interfaced with major European research actors and national funding agencies to harmonize priorities in nanotechnology and biomedical research.

History

EuroNanoMed was founded in the context of EU research policy developments linked to the Seventh Framework Programme and later aligned with priorities from the Horizon 2020 initiative, drawing participation from agencies such as the Agence Nationale de la Recherche, ANR (France), and the Deutsche Forschungsgemeinschaft. Early governance involved coordination with the European Science Foundation and engagement with transnational instruments like the ERA-NET mechanism and European Research Area policy dialogues. The network organized joint calls alongside national funding bodies including the Medical Research Council (United Kingdom), Instituto de Salud Carlos III, Fonds de la Recherche Scientifique (Belgium), and the Swedish Research Council. Key milestones included thematic calls that paralleled agendas promoted by institutions such as the European Commission Directorate-Generals and initiatives from the European Medicines Agency and the European Institute of Innovation and Technology. EuroNanoMed’s timeline intersected with programs supported by agencies like the Ministry of Education and Research (Germany), the National Science Centre (Poland), and national ministries in Italy, Spain, Portugal, Greece, and Romania.

Objectives and Scope

The network aimed to support translational projects bridging molecular diagnostics, nanocarriers, and regenerative medicine by coordinating funding from national bodies like the Swiss National Science Foundation and the Health Research Board (Ireland). Objectives included standardizing methodologies relevant to agencies such as the European Chemicals Agency and facilitating ethical oversight in line with frameworks from the Council of Europe and the European Court of Human Rights where applicable. Scope covered collaborations among universities such as Karolinska Institutet, University of Oxford, Université Pierre et Marie Curie, and research centers including the Max Planck Society and CNRS laboratories, with involvement from industry partners like Roche, Novo Nordisk, and Siemens Healthineers in project consortia. The program sought synergies with infrastructures like European Molecular Biology Laboratory, EMBL, and clinical networks including European Society of Cardiology registries.

Governance and Funding

Governance combined a central coordinating secretariat with national funding agencies and advisory boards, often referencing procedures similar to those used by European Research Council panels and evaluation processes modeled on the Marie Skłodowska-Curie Actions. Funding streams derived from partners such as Forschungsgemeinschaft, regional ministries including Ministère de l'Enseignement Supérieur et de la Recherche (France), and agencies like the Netherlands Organisation for Scientific Research. Management structures included scientific committees with experts from institutions like Imperial College London, ETH Zurich, University of Barcelona, and members drawn from regulatory backgrounds at the European Food Safety Authority and the European Centre for Disease Prevention and Control when projects touched on public health. Match-funding arrangements echoed mechanisms employed by the COST Association and the European Structural and Investment Funds.

Research Themes and Projects

Research themes encompassed nanocarrier design referenced in studies by groups at University College London, targeted imaging strategies explored by teams at University of Cambridge, and biomaterials research consistent with outputs from Politecnico di Milano laboratories. Projects addressed oncology diagnostics akin to efforts by European Organisation for Research and Treatment of Cancer consortia, antimicrobial strategies resonant with Wellcome Trust priorities, and neurodegenerative disease models studied at Institut Pasteur and MRC Laboratory of Molecular Biology. Collaborative grants involved partners such as VTT Technical Research Centre of Finland, Technion – Israel Institute of Technology, Barcelona Supercomputing Center, and corporate research from Philips, Bayer, and Johnson & Johnson. Methodological work aligned with standards from ISO committees and produced outputs useful to clinical networks like European Society for Medical Oncology and regulatory science referenced by European Medicines Agency assessments.

Partnerships and Collaborations

EuroNanoMed forged partnerships with national agencies including Fonds Wetenschappelijk Onderzoek, Research Council of Norway, and Academy of Finland, and collaborated with pan-European organizations such as European University Association and European Federation of Pharmaceutical Industries and Associations. Academic collaborations included Karlsruhe Institute of Technology, Ghent University, Università di Bologna, University of Copenhagen, and Ludwig Maximilian University of Munich. Industry and SME partners ranged from Cellectis-style biotech firms to multinational corporations like GlaxoSmithKline and infrastructure providers such as EuroBioImaging. The network interfaced with standard-setting bodies like CEN and with clinical research organizations modeled on Transcelerate Biopharma frameworks.

Impact and Outcomes

Outcomes included funded consortia that produced peer-reviewed publications involving authors from Nature Publishing Group journals, translational pipelines that entered preclinical validation in collaboration with institutions like Mayo Clinic-affiliated groups, and patents filed by partners analogous to filings with the European Patent Office. The network influenced national funding priorities at agencies such as FCT (Portugal) and ANR (France) and informed policy discussions at the European Commission and Parliament committees on research and innovation. Capacity building benefitted graduate programs at University of Porto, Trinity College Dublin, and Université de Genève, while spin-offs referenced commercialization practices seen at Cambridge Enterprise and ETH Transfer offices.

Category:European research networks